Fresh analysis indicates that people who come off blockbuster slimming jabs like semaglutide or tirzepatide may regain lost weight far faster than those who stop conventional lifestyle programs.
Research printed in a major health publication points out that while obese individuals frequently drop a large proportion of their body weight while using the jabs, the weight comes back at an average rate of 0.8 kg per month upon discontinuation.
"Individuals using such drugs should be cognizant of the potential of rapid rebound weight gain when the treatment ends," cautioned expert Dr. Susan Jebb.
Such speed of regain suggests a return to starting mass in about 18 months.
Weighing Approaches
The study, which examined dozens of trials involving over 9,000 of patients, contrasted the effects of the injectable medications with other pills.
Scientists note that people who lose weight through diet and exercise generally experience a slower weight regain—around 0.1 kg a month—once they finish.
Explaining the Rapid Regain
Nutrition scientists believe the way of the jabs accounts for the amplified rebound.
The injections mimic a natural hormone called GLP-1, which moderates feelings of fullness.
"Artificially providing GLP-1 levels far above than normal might result in the system to generate a reduced amount of its endogenous hormone, and may also diminish sensitivity to its effects," noted Dr. Adam Collins, a nutrition expert.
"Withdrawal of this GLP-1 'fix' leads to hunger is no longer kept in check, making binge eating much more probable."
An Ongoing Condition?
Health authorities recommend the jabs for individuals with weight-linked medical conditions, accompanied by prescribed lifestyle changes.
A number of clinicians argue that, considering the likelihood of relapse, the treatment is often life-long.
This view is echoed by pharmaceutical companies, who say that the results "underscore the long-term character of obesity," comparing it to managing diseases like hypertension.
User Experiences
Individuals who have stopped the medication report a intense return of appetite.
"It was like a trigger that goes on and you become extremely hungry," described one woman.
This difficulty is exacerbated if patients have not established lasting dietary or behavioural modifications during therapy.
Widespread Adoption
Survey data indicate that a significant number of adults in the UK have used weight-loss jabs in the last 12 months, with interest being substantial.
- Use is greater among women than males.
- The 40s and 50s age group shows the highest level of interest.
- Many access the medications through private healthcare rather than the NHS.
In conclusion, clinicians caution that while GLP-1 drugs are potent agents for shedding pounds, they are not a permanent solution and maintained weight loss relies on combined lifestyle management.
